Who needs direct-acting antivirals for HCV? Challenges faced in advancing HCV therapy for HIV-HCV-coinfected individuals

Antiviral Therapy

Volumn 18, Issue 5, 2013, Pages 717-721

  Klein, Marina B ^a   Rollet, Kathleen C ^a   Hull, Mark ^b,c   Cooper, Curtis ^d   Walmsley, Sharon ^e   Conway, Brian ^c   Pick, Neora ^c  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DIRECT ACTING ANTIVIRAL AGENT; EFAVIRENZ; LOPINAVIR; PEGINTERFERON ALPHA; PROTEINASE INHIBITOR; RALTEGRAVIR; RIBAVIRIN; RITONAVIR; UNCLASSIFIED DRUG;

ADULT; ALCOHOL ABUSE; ARTICLE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; DRUG TREATMENT FAILURE; EDUCATIONAL STATUS; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MONOTHERAPY; PATIENT CODING; PATIENT SELECTION; POVERTY; PRIORITY JOURNAL; RISK FACTOR; SELF REPORT; TREATMENT CONTRAINDICATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CANADA; COINFECTION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84888167789     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2484     Document Type: Article

References (20)

1. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001;33:562-569.
2. Macías J, Berenguer J, Japon MA, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 2009;50:1056-1063.
3. Berenguer J, Alvarez-Pellicer J, Martin PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009;50:407-413.
4. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-450.
5. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-459.
6. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004;292:2839-2848.
7. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004;18:F27-F36.
8. Butt AA, Kanwal F. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clin Infect Dis 2012;54:96-104.
9. Sulkowski M, Pol S, Cooper C, et al. Boceprevir + pegylated interferon + ribavirin for the treatment of HCV/HIVcoinfected patients: end of treatment (week-48) interim results. 19th Conference on Retroviruses and Opportunistic Infections. 5-8 March 2012, Seattle, WA, USA. Abstract 47.
10. Dieterich D, Soriano V, Sherman K, et al. Telaprevir in combination with pegylated interferon-alfa-2a+RBV in HCV/HIV-co-infected patients: a 24-week treatment interim analysis. 19th Conference on Retroviruses and Opportunistic Infections. 5-8 March 2012, Seattle, WA, USA. Abstract 46.
11. Klein MB, Saeed S, Yang H, et al. Cohort profile: the Canadian HIV-hepatitis C co-infection cohort study. Int J Epidemiol 2010;39:1162-1169.
12. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med 1998;158:1789-1795.
13. Victrelis™ (Boceprevir). Product monograph 2011. Merck Frosst, Kirkland, QC, Canada.
14. Incivek™ (Telaprevir tablets). Product monograph 2011. Vertex Pharmaceuticals (Canada) Incorporated, Laval, QC, Canada.
15. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-1069.
16. Weiss JJ, Alcorn MC, Rabkin JG, Dieterich DT. The critical role of medication adherence in the success of boceprevir and telaprevir in clinical practice. J Hepatol 2012;56:503-504.
17. Seden K, Back D. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions. Current opinion in HIV and AIDS 2011, 6:514-526.
18. Hulskotte E, Feng H-P, Xuan F, et al. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, lopinavir, and darunavir. 19th Conference on Retroviruses and Opportunistic Infections. 5-8 March 2012, Seattle, WA, USA. Abstract 77LB.
19. US Food and Drug Administration. FDA drug safety communication: updated information on drug interactions between Victrelis (boceprevir) and certain boosted HIV protease inhibitor drugs. (Updated 26 April 2012. Accessed 2 June 2012.) Available from http://www.fda.gov/Drugs/DrugSafety/ucm301616.htm.
20. Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravirbased regimen versus continuation of a lopinavirritonavirbased regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010;375:396-407.